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Peeking into the black box: New 
biomarkers for acute kidney injury
JM Thurman1 and CR Parikh2
The development of effective therapies for acute kidney injury (AKI) 
has been hindered by delayed diagnosis in the clinical setting, varying 
definitions of AKI, and limited prognostic information. In a study by 
Portilla et al., elevations in liver fatty acid-binding protein (L-FABP) 
were found to predict AKI in children undergoing cardiac surgery. New 
biomarkers offer the promise of earlier and more accurate diagnosis of 
AKI. Before they can be deemed clinically useful, however, they must 
undergo rigorous validation in multiple cohorts. 
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Preclinical research has revealed a great 
deal about the molecular mechanisms 
that cause acute kidney injury (AKI), 
and potential interventions have been 
identified in rodent models. These 
ﬁndings have not, however, been trans-
lated into eﬀective clinical therapies. 
There are many obstacles to the devel-
opment of therapies for AKI, including 
delayed diagnosis in the clinical setting, 
varying deﬁnitions of AKI, and limited 
tools for characterizing the mechanisms 
of injury in individual patients who may 
have sustained several renal insults.
Because we do not routinely biopsy 
patients with AKI, the severity and 
course of disease are determined almost 
exclusively by changes in the serum cre-
atinine values and urine output. Serum 
creatinine, the more reliable of the two, 
has several limitations and is not an ideal 
biomarker of AKI. It has a wide normal 
range, as its levels are aﬀected by age, 
sex, and race. It is also a poor marker 
of renal reserve, and, most importantly, 
the serum levels increase 1–3 days after 
the episode of kidney insult. To enable 
earlier diagnosis and to provide insight 
into the underlying pathophysiology in 
the individual patient, an eﬀort has also 
been made to identify better biomarkers 
through genomic and proteomic analysis 
of the serum and urine. Such markers 
will probably improve our ability to 
identify the patients at greatest risk of 
developing AKI and also enable earlier 
diagnosis of renal injury. Early interven-
tion has proven critical to the eﬀective 
therapy of many diseases, including 
acute coronary syndromes, cerebral vas-
cular accidents, and head trauma.
Several biomarkers have been investi-
gated in human populations, including 
neutrophil gelatinase-associated lipoca-
lin (NGAL),1–3 interleukin-18 (IL-18),4 
and KIM-1.5 Portilla et al.6 (this 
issue) demonstrate that another urine 
protein, liver fatty acid-binding protein 
(L-FABP), predicts the development of 
AKI (deﬁned as a 50% increase in the 
serum creatinine) in children under-
going cardiac surgery. They found 
that increases in the urinary L-FABP 
within 4 hours after the cardiac surgery 
predicted the subsequent develop-
ment of AKI with an accuracy of 81% 
(area under the curve). Elevations in 
serum creatinine, in contrast, occurred 
between 24 and 72 hours after cardio-
pulmonary bypass.
L-FABP is expressed by proximal 
tubules. Urinary levels of the pro-
tein have previously been shown to 
increase in patients who develop AKI 
after exposure to intravenous contrast 
and to be predictive of progression in 
patients with chronic kidney disease.7 
In a rodent model, the expression of 
L-FABP by the renal tubules increased 
in response to treatment with cispla-
tin.8 Tubular expression of L-FABP 
may, therefore, be a sensitive indicator 
of a number of diﬀerent stressors of the 
tubular epithelial cells.
Pediatric cardiac surgery is an 
ideal clinical setting for performing 
initial ‘bench-to-bedside’ studies in 
development of diagnostic tests. The 
pediatric population is free of comor-
bidities commonly seen in adults. Fur-
thermore, the timing of kidney injury 
(occurring in the intraoperative period) 
is known, and this information can be 
used as a reference point for under-
standing the trend of biomarker levels. 
So far, six biomarkers—NGAL, IL-18, 
KIM-1, NAG, MMP, and now L-FABP—
have been evaluated in the setting of 
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adult2 or pediatric cardiac surgery.1,4,5 
The performance of these biomarkers for 
diagnosis of AKI (50% increase in serum 
creatinine in all studies) at various times 
after cardiac surgery is demonstrated in 
Figure 1. Although this is a good model 
for translation of basic-science ﬁndings, 
the generalizability of the ﬁndings in this 
pediatric population may be limited. The 
accuracy and discriminatory properties 
of these markers are often much poorer 
in an adult population with comorbidi-
ties (chronic kidney disease, diabetes, 
hypertension), or in patients who have 
sustained multiple renal insults or in 
whom the timing of injury is not known, 
as in critically ill patients. NGAL, for 
example, had an area under the curve 
of 99% in the pediatric cardiac surgery 
setting,1 but this fell to 80% in an adult 
cardiac surgery cohort2 and to 78% in 
pediatric critically ill patients.3
A surprisingly high percentage of 
patients (52%) developed AKI in the 
study by Portilla et al.6 The authors do 
not mention whether consecutive cases 
were enrolled, introducing the pos-
sibility of selection bias. Elevations in 
creatinine persisted for at least 5 days, 
suggesting that the rise in creatinine 
was probably due to true renal injury 
and not a functional change due to pre-
renal causes. The authors do not indicate 
whether any patients needed dialysis or 
died after surgery, and levels of L-FABP 
in patients with higher changes in serum 
creatinine are not reported.
The sensitivity and specificity of 
L-FABP in this pediatric cohort are 
modest (71% and 68%, respectively), 
particularly given that NGAL was a 
perfect test in the same population. 
Furthermore, the increase of L-FABP 
in patients who did not develop AKI (a 
change of approximately 29 ng/mg of 
creatinine) was similar in magnitude to 
the change in patients who did develop 
AKI in response to contrast received 
during non-emergent coronary angi-
ography (an increase of approximately 
28 ng/mg of creatinine).9 Portilla et 
al.6 suggest that this may be due to the 
sensitive response of L-FABP to renal 
ischemia. The ﬁnding hints at the dif-
ﬁculty of interpreting urine L-FABP in 
a mixed group of patients, particularly 
as baseline levels also increase in 
patients with progressive chronic kid-
ney disease.7 This increase in levels of 
L-FABP with multiple types of kidney 
injury, however, could potentially make 
L-FABP a useful marker of subclinical 
stress or injury to the tubules. This could 
also possibly be utilized in patients in 
whom the serum creatinine is unlikely 
to rise with mild insults to the kidney. In 
patients with liver disease, for example, 
a low urine L-FABP might help verify 
that a patient has normal kidney func-
tion and assist with deciding between 
combined kidney–liver transplantation 
or liver transplantation alone.
Before a new biomarker can be 
deemed clinically useful, it requires val-
idation in multiple cohorts, it must be 
reliable, and it must provide incremental 
prognostic information over traditional 
markers and models. L-FABP should 
now, for example, be tested in other 
cohorts such as adult cardiac surgery 
patients and critically ill patients to see 
whether there is any attenuation in accu-
racy. A systematic phased approach and 
multidisciplinary involvement are essen-
tial for translating urinary biomarkers 
into diagnostic tests for AKI. Carefully 
designed phase 2 and phase 3 studies are 
needed in order to identify the potential 
of each marker for further development. 
An example of a phased development 
approach for diagnostic tests has been 
described by Pepe et al.10
We have now identiﬁed several can-
didate biomarkers for the diagnosis of 
AKI. The broad applicability of a good 
biomarker requires that it be robust 
and easily interpretable. A number 
of recent studies have demonstrated 
that even small changes in the serum 
creatinine are associated with worse 
clinical outcomes.11 It is interesting that 
even after decades of measuring serum 
creatinines we are still learning how to 
interpret the meaning of this routine 
test. In this light, the challenge of char-
acterizing and validating multiple new 
biomarkers in the background of serum 
creatinine is a daunting task. Given how 
important it is for the development of 
new treatments for AKI, however, the 
further evaluation of these candidates 
should not depend on the initiative of 
individual investigators. Instead, a dedi-
cated validation program supported by 
Figure 1 | Accuracy of biomarkers for the diagnosis of AKI after cardiac surgery. Six 
biomarkers have been tested for their ability to diagnose AKI (defined as a 50% increase in the 
serum creatinine concentration) in patients who underwent cardiac surgery. This graph depicts 
the changes in area under the curve (AUC) for the different biomarkers after cardiac surgery.2,4–
6 Biomarkers such as neutrophil gelatinase-associated lipocalin (NGAL) and liver fatty acid-
binding protein (L-FABP) have higher accuracy early, and then the accuracy diminishes after 
4–6 hours after surgery (the AUC for L-FABP at 12 hours is estimated). Biomarkers such as 
interleukin-18 (IL-18) and KIM-1 have lower accuracy at 2–4 hours after surgery, but the 
accuracy increases at 12–24 hours after surgery. The solid bar demonstrates that serum 
creatinine increases by 50% in these studies at a much later time (24–72 hours) after surgery.
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the National Institutes of Health could 
potentially test the most promising 
biomarkers in various cohorts, perform 
quality-control studies, identify cutoﬀs, 
and design larger phase 3 and phase 4 
trials. Programs to coordinate and 
accelerate the development of biomark-
ers have been developed in recent years, 
such as the Early Detection Research 
Network established by the National 
Cancer Institute (see http://edrn.nci.
nih.gov). Comprehensive evaluation of 
biomarkers in large patient populations 
could reveal fascinating diversity of bio-
chemical patterns within the large group 
of AKI patients whom we currently 
identify solely by the elevation in their 
serum creatinine. The most important 
result, though, would be the discovery 
of a simple test that could diagnose renal 
injury reliably at the time of renal insult 
and before markers of ﬁltration, such as 
creatinine and cystatin C, rise.
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